Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 2Phase 1 2Phase NA 1Phase 3 1

Status

Completed 2Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

NIH 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 2Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Gynecologic 1Dermatologic 1

Conditions

Lymphoma 34Leukemia 34Lymphoma, Follicular 27Melanoma 25Leukemia, Lymphocytic, Chronic, B-Cell 22Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Lymphoma, Non-Hodgkin 20Leukemia, Myeloid, Acute 20Multiple Myeloma 18Breast Neoplasms 18Lymphoma, Large B-Cell, Diffuse 17Prostatic Neoplasms 15Lymphoma, Mantle-Cell 15Lymphoma, Large-Cell, Immunoblastic 15Neuroblastoma 14Neoplasms, Plasma Cell 13Myelodysplastic Syndromes 13Leukemia, Myelogenous, Chronic, BCR-ABL Positive 13Hodgkin Disease 13Burkitt Lymphoma 13Leukemia, Myeloid, Chronic-Phase 12Neoplasm Metastasis 11Lymphoma, B-Cell, Marginal Zone 11Lung Neoplasms 10Glioblastoma 9Carcinoma, Non-Small-Cell Lung 9Myeloproliferative Disorders 8Leukemia, Myeloid, Accelerated Phase 8Ovarian Neoplasms 7Gliosarcoma 7

Interventions

Gemcitabine 53Bevacizumab 52Cyclophosphamide 49Docetaxel 42Carboplatin 40pembrolizumab 37Paclitaxel 36Fluorouracil 36Cisplatin 35Radiotherapy 31Oxaliplatin 31Capecitabine 29Irinotecan 28Dexamethasone 27Leucovorin 25Cetuximab 25Nivolumab 24Doxorubicin 22Drug Therapy 21Erlotinib Hydrochloride 20Pemetrexed 19durvalumab 18trametinib 17fludarabine 16atezolizumab 16Trastuzumab 16Sunitinib 16Rituximab 16Prednisone 16Sorafenib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms × sargramostim × Clear all
NCT00019097 2024-03-04

Vaccine Therapy in Treating Patients With Multiple Myeloma

National Cancer Institute (NCI)

Phase 2 Completed
Other hematologic neoplasmPlasma cell

Multiple Myeloma, Neoplasms, Hematologic Neoplasms, Genetic Diseases, Inborn, Neoplasms, Plasma Cell

NCT00019890 2024-03-04

Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma

National Cancer Institute (NCI)

Phase 2 Completed
Dermatologic

Melanoma, Neoplasms, Skin Neoplasms

NCT04300244 2024-02-29

NIPU

Oslo University Hospital

Phase 2 Active not recruiting
118 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant, Lung Neoplasms, Mesothelioma, Neoplasms

NCT05344209 2023-11-09

LUNGVAC

Vestre Viken Hospital Trust

Phase 2 Recruiting
138 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT00001827 2017-10-06

p53 Vaccine for Ovarian Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
21 enrolled
Gynecologic

Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡